ArticleEBioMedicine2020
Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Guideline
- Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.European urology · 2022Trial
- Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma.Histopathology · 2026Review
- Determinants of pancreatic tropism in metastatic renal cell carcinoma.JCI insight · 2026Article
- HMGA2 links morphological evolution and microenvironment dynamics to systemic therapy response in clear cell renal cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- 3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma.Journal of neuropathology and experimental neurology · 2025Article
- MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology.Genome medicine · 2025Article
- Determinants of late metastases in renal cell carcinoma.Journal of the National Cancer Institute · 2025Article
- Comparison of Histologic Parameters and Predictive Gene Signatures in Clear Cell Renal Cell Carcinoma Response to Systemic Therapy.Pathology international · 2025Article
- Preoperative prediction of WHO/ISUP grade of ccRCC using intratumoral and peritumoral habitat imaging: multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Evidence of DNA methylation heterogeneity and epipolymorphism in kidney cancer tissue samples.Oncogene · 2025Article
- Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.Nature communications · 2025Article
- In Pursuit of KI-RADS: Toward a Single, Evidence-based Imaging Classification of Renal Masses.Radiology · 2025Review
- Conserved patterns of transcriptional dysregulation, heterogeneity, and cell states in clear cell kidney cancer.Cell reports · 2025Article
- Association of Histologic Growth Patterns and Some Histopathologic Features in Clear Cell Renal Cell Carcinoma with Patient's Survival after Nephrectomy: A Cross-Sectional Study.Iranian journal of pathology · 2025Article
- Exploring Tumor Heterogeneity: Radiogenomic Assessment of ADFP in Low WHO/ISUP Grade Clear Cell Renal Cell Carcinoma.Cancers · 2024Article
- Histopathology Based AI Model Predicts Anti-Angiogenic Therapy Response in Renal Cancer Clinical Trial.ArXiv · 2024Article
- Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.Journal of translational medicine · 2023Article
- The expanding role of BAP1 in clear cell renal cell carcinoma.Human pathology · 2023Review
- Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.Cancer cell · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is a particularly challenging tumor type because of its extensive phenotypic variability as well as intra-tumoral heterogeneity (ITH). Clinically, this complexity has been reduced to a handful of pathological variables such as stage, grade and necrosis, but these variables fail to capture the breadth of the disease. How different phenotypes affect patient prognosis and influence therapeutic response is poorly understood. Extensive ITH illustrates remarkable plasticity, providing a framework to study tumor evolution. While multiregional genomic analyses have shown evolution from an ancient clone that acquires metastatic competency over time, these studies have been conducted agnostic to morphological cues and phenotypic plasticity.
methodsWe established a systematic ontology of ccRCC phenotypic variability by developing a multi-scale framework along three fundamental axes: tumor architecture, cytology and the microenvironment. We defined 33 parameters, which we comprehensively evaluated in 549 consecutive ccRCCs retrospectively. We systematically evaluated the impact of each parameter on patient outcomes, and assessed their contribution through multivariate analyses. We measured therapeutic impact in the context of anti-angiogenic therapies. We applied dimensionality reduction by t-distributed stochastic neighbor embedding (t-SNE) algorithms to tumor architectures for the study of tumor evolution superimposing tumor size and grade vectors. Evolutionary models were refined through empirical analyses of directed evolution of tumor intravascular extensions, and metastatic competency (as determined by tumor reconstitution in a heterologous host).
findingsWe discovered several novel ccRCC phenotypes, developed an integrated taxonomy, and identified features that improve current prognostic models. We identified a subset of ccRCCs refractory to anti-angiogenic therapies. We developed a model of tumor evolution, which revealed converging evolutionary trajectories into an aggressive type.
interpretationThis work serves as a paradigm for deconvoluting tumor complexity and illustrates how morphological analyses can improve our understanding of ccRCC pleiotropy. We identified several subtypes associated with aggressive biology, and differential response to targeted therapies. By analyzing patterns of spatial and temporal co-occurrence, intravascular tumor extensions and metastatic competency, we were able to identify distinct trajectories of convergent phenotypic evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.